For iPSC cartilage, IL-1α treatment was initiated following 21 days of
chondrogenic pellet culture. IL-1α treatment of native cartilage was begun after 2
days of equilibration in media. For both cartilages, treatment with recombinant mouse
IL-1α (R&D Systems) was conducted in serum-free chondrogenic medium.
Dose-response experiments with iPSC cartilage were conducted using control, 10 pg/ml, 100
pg/ml, or 1 ng/ml doses. Since the treatment of native articular cartilage with IL-1 has
been conducted regularly in the literature (32 (link),
33 (link)), only the control and 1 ng/ml doses were used
for native mouse cartilage samples. For gene expression studies in iPSC cartilage, IL-1
was given for 24 hrs. All other IL-1α treatments, in both iPSC and native
cartilage, were conducted for 3 days.
chondrogenic pellet culture. IL-1α treatment of native cartilage was begun after 2
days of equilibration in media. For both cartilages, treatment with recombinant mouse
IL-1α (R&D Systems) was conducted in serum-free chondrogenic medium.
Dose-response experiments with iPSC cartilage were conducted using control, 10 pg/ml, 100
pg/ml, or 1 ng/ml doses. Since the treatment of native articular cartilage with IL-1 has
been conducted regularly in the literature (32 (link),
33 (link)), only the control and 1 ng/ml doses were used
for native mouse cartilage samples. For gene expression studies in iPSC cartilage, IL-1
was given for 24 hrs. All other IL-1α treatments, in both iPSC and native
cartilage, were conducted for 3 days.
